Alzheimer’s Disease in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

The Alzheimer’s Disease therapeutics market is entering a period of significant expansion, supported by advances in disease-modifying treatments and the growing approval of anti-Aβ monoclonal antibodies. As treatment innovation accelerates and diagnosis improves, the market is poised for substantial long-term growth across major global healthcare systems.

GlobalData estimates that the Alzheimer’s Disease (AD) market across the eight major markets (8MM)—the US, France, Germany, Italy, Spain, the UK, Japan, and China—was valued at $2.4 billion in 2023. The market encompasses sales of both symptomatic therapies and disease-modifying treatments, reflecting the evolving treatment landscape.

The US and China dominate global sales, contributing $1.1 billion (44.7%) and $915.2 million (38.8%), respectively. At the other end of the spectrum, France represents the smallest share at 1.1%, influenced by a lower prevalent population and the absence of reimbursement for current symptomatic therapies, resulting in reduced treatment rates. By 2033, the AD market across the 8MM is projected to reach $17.0 billion, growing at a compound annual growth rate (CAGR) of 21.8%.

Scope

This report provides a comprehensive analysis of the Alzheimer’s Disease therapeutics market across the eight major markets, supported by an Excel-based forecast model extending through 2033. Coverage includes:

  • Overview of Alzheimer’s Disease, including epidemiology, symptoms, diagnosis, and disease management

  • Annualized therapeutics market revenue forecasts from 2023 to 2033

  • Analysis of cost of therapy per patient and treatment usage patterns

  • Strategic competitor assessment and overall market characterization

  • Identification of unmet needs within the Alzheimer’s treatment landscape

  • Clinical trial mapping and analysis of its implications for the therapeutics market

  • Comprehensive pipeline analysis evaluating emerging trends and mechanisms of action under development

  • Profiles of the most promising late-stage candidates

  • Assessment of current and future competition within the global Alzheimer’s Disease therapeutics market

  • Detailed review of key industry drivers, restraints, and challenges, with qualitative analysis of their market implications

How industry leaders are using this report

  • Develop in-licensing and out-licensing strategies by evaluating pipeline products, technologies, and companies with strong development portfolios

  • Build business strategies by understanding the trends shaping the 8MM Alzheimer’s Disease therapeutics market

  • Identify innovative products, technologies, and companies likely to influence future market dynamics

  • Formulate effective sales and marketing strategies using competitive landscape analysis and performance benchmarking

  • Detect emerging players with potentially strong product portfolios and create counter-strategies

  • Prioritize market segments presenting the greatest opportunities for investment, consolidation, and strategic partnerships

Reasons to Buy

  • Develop and design in-licensing and out-licensing strategies through detailed pipeline analysis

  • Understand the major trends driving growth in the 8MM Alzheimer’s Disease therapeutics market

  • Drive revenue opportunities by identifying innovative products, technologies, and high-impact companies

  • Strengthen sales and marketing strategies through competitive intelligence

  • Gain visibility into emerging competitors and evolving product portfolios

  • Identify high-opportunity market segments for investments and partnerships

Who should buy this report

  • Pharmaceutical and Biopharmaceutical Companies

  • Alzheimer’s and CNS Therapeutics Developers

  • Business Development and Licensing Teams

  • Commercial Strategy and Market Intelligence Functions

  • Healthcare Investors and Strategic Partnerships Teams

  • Consultants and Industry Advisors

Eli Lilly and Co
Otsuka Pharmaceutical Co Ltd
Novartis AG
Biogen Inc
Eisai Co Ltd
Suven Life Sciences Ltd
Towa Pharmaceutical Co Ltd
AB Science SA
H. Lundbeck AS
Neurimmune Holding AG
Annovis Bio Inc
Teikoku Seiyaku Co Ltd
AbbVie Inc
BioVie Inc
Alzheon Inc
Axsome Therapeutics Inc
TauRx Pharmaceuticals Ltd
Anavex Life Sciences Corp
Shanghai Green Valley Pharmaceutical Co Ltd
Johnson & Johnson
Corium LLC
Bristol-Myers Squibb Co
Ono Pharmaceutical Co Ltd
Novo Nordisk AS
Daiichi Sankyo Co Ltd
AriBio Co Ltd
Luye Pharma Group Ltd
BioXcel Therapeutics Inc
AlphaCognition Inc
Biomed Industries Inc
Cerecin Inc

Table of Contents

List of Contents

List of Tables

List of Figures

1 Alzheimer’s Disease: Executive Summary

1.1 Summary of changes

1.2 Executive summary

1.3 Alzheimer’s market forecast to see double-digit sales growth out to 2033

1.4 Eisai, Biogen, and Lilly are forecast to lead the AD market in 2033

1.5 Opportunities to fulfil key unmet needs will remain

1.6 Novel late-stage pipeline drugs will be a key driver of growth

1.7 What Do Physicians Think?

2 Introduction

2.1 Catalyst

2.2 Related reports

2.3 Upcoming reports

3 Disease Overview

3.1 Etiology

3.1.1 Risk genes

3.1.2 Deterministic genes

3.1.3 Protective genes

3.1.4 Metabolic disruption

3.2 Pathophysiology

3.2.1 Structural changes in the brain

3.2.2 Degenerative process

3.2.3 Aβ plaques

3.2.4 Neurofibrillary tangles

3.2.5 Neurotransmitter deficiencies

3.2.6 Oxidative stress

3.3 Biomarkers / targets of interest

3.4 Disease staging systems

3.5 Symptoms and prognosis

4 Epidemiology

4.1 Disease Background

4.2 Risk Factors and Comorbidities

4.3 Global and Historical Trends

4.4 Forecast Methodology

4.4.1 Sources

4.4.2 Forecast Assumptions and Methods

4.4.3 Forecast assumptions and methods: total prevalent cases of AD by DSM-IV criteria

4.4.4 Forecast assumptions and methods: total prevalent cases of AD by severity

4.4.5 Forecast assumptions and methods: total prevalent cases of preclinical AD

4.4.6 Forecast assumptions and methods: total prevalent cases of MCI

4.5 Epidemiological Forecast for AD (2023-33)

4.5.1 Total prevalent cases of AD by DSM-IV criteria

4.5.2 Age-specific total prevalent cases of AD by DSM-IV criteria

4.5.3 Sex-specific total prevalent cases of AD by DSM-IV criteria

4.5.4 Total prevalent cases of AD by severity

4.5.5 Total prevalent cases of preclinical AD

4.5.6 Age-specific total prevalent cases of preclinical AD

4.5.7 Sex-specific total prevalent cases of preclinical AD

4.5.8 Total prevalent cases of MCI

4.5.9 Age-specific total prevalent cases of MCI

4.5.10 Sex-specific total prevalent cases of MCI

4.6 Discussion

4.6.1 Epidemiological forecast insight

4.6.2 COVID-19 impact

4.6.3 Limitations of the Analysis

4.6.4 Strengths of the Analysis

5 Disease Management

5.1 Diagnosis and treatment overview

5.2 KOL insights on disease management

6 Current Treatment Options

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 More efficacious DMTs

7.3 Improved control of behavioral symptoms

7.4 Symptomatic drugs for cognition

7.5 Improving diagnosis earlier in the disease progression

7.6 Access to treatment

8 R&D Strategies

8.1 Overview

8.1.1 Targeting Aβ

8.1.2 Novel MOAs

8.1.3 Targeting agitation and psychosis

8.1.4 Targeting preclinical AD

8.1.5 Combination therapies

8.1.6 Non-pharmacological treatments

8.2 Clinical Trials Design

8.2.1 Inclusion/exclusion criteria

8.2.2 Endpoints

8.2.3 Use of biomarkers in trial design

9 Pipeline Assessment

9.1 Overview

9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive Assessment

10.2.1 Potential DMTs

10.2.2 Therapies for agitation and psychosis associated with AD

11 Current and Future Players

11.1 Overview

11.2 Deal-Making Trends

12 Market Outlook

12.1 Global Markets

12.1.1 Forecast

12.1.2 Drivers and barriers – global issues

12.2 US

12.2.1 Forecast

12.2.2 Key Events

12.2.3 Drivers and Barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key Events

12.3.3 Drivers and Barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key events

12.4.3 Drivers and barriers

12.5 China

12.5.1 Forecast

12.5.2 Key events

12.5.3 Drivers and barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 AD clinical development pipeline

13.4 Methodology

13.4.1 Forecasting methodology

13.5 Primary research – KOLs interviewed for this report

13.6 Primary research – prescriber survey

13.7 About the authors

13.7.1 Analyst

13.7.2 Therapy Area Director

13.7.3 Epidemiologist

13.7.4 Managing Epidemiologist

13.7.5 Vice President of Disease Intelligence and Epidemiology

13.7.6 Global Head of Pharma Research, Analysis, and Competitive Intelligence

About GlobalData

Contact Us

Alzheimer’s Disease in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033 standard reports
Currency USD
$17,995

Can be used by individual purchaser only

$53,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Alzheimer’s Disease in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Alzheimer’s Disease in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033 in real time.

  • Access a live Alzheimer’s Disease in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.